The radiobiological data obtained from a multicentre clinical trial of the British Institute of Radiology, which compared the treatment of carcinoma of the laryngo-pharynx by 3 fractions per week (3F/wk) with 5 fractions per week (5F/wk) radiotherapy, have been studied. The trial involved an intake of 734 patients between 1966 and 1975. The number of fractions, overall treatment time and total doses used by different treatment centres ranges from 9 to 40 fractions, 18 to 70 days and 3880 to 7800 cGy, respectively. An 11-13% reduction in the total radiation dose was applied for treatments with 3F/wk as compared with 5F/wk in centres treating over 6 weeks and 3 weeks, respectively. All patients were followed for 10 years from the start of treatment. Different types of early and late normal-tissue reactions were investigated, ranging from a low percentage incidence of perichondritis to 95% for slight early reactions. Greater than 80% of the late normal-tissue reactions seen were observed within the first year after the start of treatment, and 96% were observed within the first 5 years. There was no statistically significant difference in the normal-tissue event-free rates between the 3F/wk and 5F/wk treatment groups. This finding did not differ when different major treatment centres were studied separately. For a number of end-points, alpha/beta ratios and N- and T-exponents of a modified nominal standard dose (NSD) formula have been calculated.

Download full-text PDF

Source
http://dx.doi.org/10.1259/0007-1285-64-768-1122DOI Listing

Publication Analysis

Top Keywords

fractions week
16
british institute
8
institute radiology
8
treatment
8
treatment carcinoma
8
carcinoma laryngo-pharynx
8
treatment centres
8
start treatment
8
late normal-tissue
8
normal-tissue reactions
8

Similar Publications

Background: Myelin integrity is central to healthy brains and is increasingly shown to be compromised in neurodegenerative diseases. Diffusion- and susceptibility-based MRI metrics can detect myelin changes. We show advanced diffusion and susceptibility metrics can detect degenerative myelin changes in ex vivo AD and HD mouse models.

View Article and Find Full Text PDF

Background: We have recently published that overexpressing a constitutively active form of the insulin receptor beta subunit (IR-β) in hippocampal neurons ameliorates spatial memory performance in the F344 rat model of aging (Frazier et al., 2020). Because astrocytes express IRs and are central to cellular energy and information transfer in the brain, here we focus on the knockdown of IR in astrocytes of the primary somatosensory cortex (S1) in the 5xFAD animal model.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

University of Kentucky, Lexington, KY, USA.

Background: Amylin is a systemic hormone that is co-secreted with insulin from pancreatic β-cells. Amylin co-aggregates with brain parenchymal and vascular β-amyloid in persons with Alzheimer's dementia. The present pilot study sought to assess the safety and side effects during and after the treatment period of passive amylin immunotherapy in the APP/PS1 mouse model of Alzheimer's disease.

View Article and Find Full Text PDF

Background: Myelin integrity is central to healthy brains and is increasingly shown to be compromised in neurodegenerative diseases. Diffusion- and susceptibility-based MRI metrics can detect myelin changes. We show advanced diffusion and susceptibility metrics can detect degenerative myelin changes in ex vivo AD and HD mouse models.

View Article and Find Full Text PDF

Introduction: In the present study, we evaluated the impact of empagliflozin on serum levels of oxidative stress parameters in individuals with type 2 diabetes (T2DM) who also suffer from heart failure with Reduced Ejection Fraction (HFrEF).

Methods: In this prospective, single-center clinical trial, 80 patients with T2DM and HFrEF, stabilized on guideline-directed heart failure therapy and classified as New York Heart Association functional (NYHA) functional classes II or III, were randomized to receive either empagliflozin (10 mg/daily) or a matching placebo for a duration of 12 weeks. Serum levels of malondialdehyde (MDA), along with the activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx), were measured at baseline and after the 12-week treatment period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!